Vidaza azacitidine: Final Phase I/II data

Final data from 35 evaluable patients in the Phase II portion of a Phase I/II trial showed that Vidaza plus Revlimid lenalidomide led to and overall response rate of 72%, 15 (42%) complete responses, 11 (28%) patients achieving hematologic improvement and 3 cases of progressive disease. Median duration of response was 16 months. For the complete responders, median overall survival was 27 months, and 7 (50%) progressed to acute myelogenous leukemia (AML) at a median of 20 months from achieving complete response. ...